Visiongain Publishes Allergy Immunotherapy Market Report to 2031

11 March 2021
Pharma

Visiongain has published a new report on Allergy Immunotherapy Market Report to 2031: Forecasts by Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT) (Tablets and Drops)), By Allergy Type (Pollens, House Dust Mites, Mould, Animal Dander, Bee Venom, Cockroaches/Insects, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) PLUS COVID-19 Recovery Scenarios.

Global Allergy Immunotherapy market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.

COVID-19 Impact on Allergy Immunotherapy Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Allergy Immunotherapy market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. In contrast, the rising research & development activities for developing novel treatments against COVID-19 is creating a lucrative opportunity for the companies. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers

Increasing Occurrence of Allergies Calls for Effective Treatments
The increasing occurrence of allergies year-on-year globally is driving demand for effective allergy immunotherapy. For the case, allergic rhinitis is a widely occurring allergy across the globe, suffering approximately 10% to 30% of the worldwide population. As per the assessment of the AAAAI, nearly 7.8% of the people above 18 are more likely to develop allergic rhinitis in the U.S. Thus generating demand for therapies to improve the lifestyle and provide relief from the effects of the allergy. Moreover, skin allergies, food allergies, and asthma are also relatively predominant around the world and continue to push the demand for allergy immunotherapy.

According to the Allergy and Clinical Immunology (JACI) assessed that 2-37% of the European people have reported food allergy. As individuals become progressively aware of the convenience of these treatments, a growing number of people are ready to pursue treatment, fueling the global allergy immunotherapy market growth in the given timeframe.

Huge Demand For Innovative Procedures
The increasing prevalence of allergies and the successive spending on treatments are allowing key players to improve their treatment offerings. Global players operating in the market are improving the existing SLIT drugs, which is clinically verified against atopic dermatitis, airway allergies, and a few food allergies. The latest surveys have recommended that SLIT continue to be a popular choice among people over SCIT, despite its limitations, due to its convenience. Furthermore, it has been well-known that the occurrence of food allergy increases 10% each year, leading to greater demand for immunotherapy.

At the same time, oral immunotherapy is gaining importance among healthcare professionals and people, particularly in the treatment of allergic rhinitis. Oral immunotherapy is used to control the occurrence of allergic reactions triggered by unintentional allergen contact with minimal levels of tolerance. As a result, key players are concentrating on enhancing their offerings on oral immunotherapy.

Moreover, factors such as rising levels of pollution, altering consumption habits, changing lifestyle, and growing consumption of alcohol is subsequently increasing the occurrence of skin and other allergies, further enhancing target industry growth.

Market Opportunities

Novel Product Launches in Sublingual Immunotherapy Offer Lucrative Growth Opportunities
The U.S. Food and Drug Administration (FDA) sanction for sublingual immunotherapy is creating a lucrative opportunity for the target industry growth. The launch of innovative treatments such as Grastek, Oralair, and Ragwitek, has a positive impact on the global allergy immunotherapy market growth. Besides, the progress of Odactra to cure the sensitivity triggered by house dust mite is expected to prompt the growth of the target market.

Competitive Landscape
Key players operating in the global Allergy Immunotherapy market are ASIT Biotech, Mylan N.V., Circassia, Merck KGaA, LETIPharma, Adamis Pharmaceuticals Corporation, Allergy Therapeutics, Stallergenes Greer plc, ALK-Abelló A/S, HAL Allergy B.V., DESENTUM OY, HollisterStier Allergy, and DBV Technologies SA.

The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Allergy Treatment market. For example, on 17th September 2020, Dr Reddy's Laboratories launched an over-the-counter (OTC) eye allergy drop Olopatadine Hydrochloride Ophthalmic Solution in the U.S. market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever